Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

Trial Status: active

This phase II trial tests how well azacitidine and venetoclax work to reduce measurable residual disease in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia (AML). Minimal residual disease (MRD) is when a small number of cancer cells from the bone marrow remain in the body during or after treatment. People with MRD have been shown to have a higher risk of cancer coming back after allogeneic stem cell transplant (relapse). Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving azacitidine and venetoclax may reduce MRD in patients undergoing allogeneic stem cell transplantation for AML.